Rocket Pharmaceuticals said Friday that the Food and Drug Administration rejected its gene therapy for an ultra-rare, sometimes fatal immuno-deficiency syndrome, saying the company needed to submit more information to prove it can safely manufacture the product.
The New York-based biotech said the FDA asked for only “limited” additional information. A spokesperson added the company remains “deeply committed to getting this treatment approved.”
The rejection is another setback for a class of gene therapies that have held tremendous promise for patients with rare blood and immune disorders but have proven exceptionally difficult to manufacture and scale.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect